Mr. Alexei Marko is Director of Neovasc Inc. Mr. Markos 18 years of experience in the medical device field spans product development, sales and marketing and executive management. Mr. Marko has held management positions with Neovasc predecessor companies since 1999 and assumed the role of CEO in 2008 in conjunction with the companys expansion and restructuring. Mr. Marko was appointed to the Companys board of directors on June 12, 2003 and is a resident of British Columbia, Canada. In October 2007, Mr. Marko was appointed President and Chief Operating Officer of Medical Ventures Corporationration, a predecessor company. Previously, Mr. Marko was the Vice President and Chief Operating Officer and Vice President, Development and Engineering of MEV. Mr. Marko is a listed inventor on a number of issued or pending patents related to medical technologies. He is also a registered professional engineer, and sits on the board of directors for the Medical Device Development Centre in Vancouver. In 2005, he was named one of Business in Vancouvers Top Forty Under 40 in recognition of his achievements
Age: 42 CEO Since 2018Marko completed both his B.A.Sc. at Queen?s University and an M.A.Sc. in electrical engineering at the University of British Columbia, specializing in medical device development. He is a registered professional engineer
Management EfficiencyThe company has return on total asset (ROA) of (32.56) % which means that it has lost $32.56 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (575.51) % meaning that it generated substantial loss on money invested by shareholders.
Entity SummaryNeovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. Neovasc is traded on Frankfurt Stock Exchange in Germany.Neovasc (G5Z1) is traded on Frankfurt Stock Exchange in Germany and employs 110 people.
Neovasc Leadership Team
|Vicki Bebeau, Vice President - Clinical Affairs|
|Brian McPherson, COO|
|Fred Colen, President CEO|
|Steven Rubin, Independent Director|
|William ONeill, Independent Director|
|Christopher Clark, CFO, Corporate Secretary|
|Alexei Marko, CEO, Director|
|Douglas Janzen, Independent Director|
|Jane Hsiao, Independent Director|
|Randy Lane, Vice President - Research & Development|
|Paul Geyer, Chairman of the Board|
Stock Performance Indicators
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
|All Next||Launch Module|
Build Optimal Portfolios
Align your risk with return expectations
Please also check Risk vs Return Analysis. Please also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.